Pharmacoresistance, a significant challenge in biopharmaceutics, refers to the reduced responsiveness of patients to therapeutic treatments over time. This phenomenon particularly impacts the efficacy of biopharmaceuticals, including protein-based drugs and monoclonal antibodies. The complexity of biological systems often leads to diverse mechanisms underlying pharmacoresistance, such as alterations in drug targets, impaired drug transport, or immune responses.
In the realm of biopharmaceutics, understanding and addressing pharmacoresistance is crucial for optimizing treatment outcomes. Researchers and pharmaceutical developers strive to unravel the underlying molecular mechanisms, employing innovative strategies to overcome resistance and enhance the therapeutic effectiveness of biopharmaceuticals. This may involve the design of novel drug delivery systems, combination therapies, or the development of next-generation biopharmaceuticals with improved resistance profiles.
The study and mitigation of pharmacoresistance in biopharmaceutics underscore the continuous evolution of strategies to ensure the sustained efficacy of these advanced therapeutic agents, contributing to the advancement of personalized and more effective healthcare solutions.
Submit your abstract Today
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India